Professor John Crown was awarded the DCU President’s Impact Award for research he leads at the National Institute for Cellular Biotechnology (NICB) to improve the treatment options available to women with metastatic HER2-positive breast cancer. Under his leadership, a new drug combination to treat women with this type of breast cancer, that is based on prior preclinical studies from the Cancer Clinical Research Trust (CCRT) research team based in the NICB, has entered clinical development in a recently opened Phase 1 clinical trial named CAROLINE-1. The CAROLINE-1 study received support from CCRT, The Caroline Foundation, BreastPredict and Puma Biotechnology Inc.
Similar Posts
The 18th International Symposium on Translational Research in Oncology, Sept 24th-26th 2025
PROGRAMME Wednesday, 24th September 2025 Lansdowne Suite, Herbert Park Hotel Wednesday, 24thSeptember 2025, Lansdowne Suite, Herbert…
Glin Estuary Swim
A brave 35 swimmers took to the choppy waters of the Shannon Estuary, in Glin, on…
Register for the 19th International Symposium on Translational Research in Oncology, Sept 23rd-25th 2026
Click here to register for the 19th International Symposium on Translational Research in Oncology. PROGRAMME Please…
First-in-world, Caroline-1 clinical trial, will commence this month at St. Vincent’s University Hospital under the leadership of Professor John Crown
As a result of many years of collaborative research by CCRT and The Caroline Foundation funded researchers based…
Celebrating the Knockaville Cake Sale
Huge thanks goes to Marcella Bell and the The Knockaville Cake Sale Committee who have had…
Dr Dennis Slamon, UCLA, awarded UCD’s highest honour, the Ulysses Medal
While in Dublin, for the 17th International Symposium on Translational Research in Oncology, Dr Dennis Slamon…